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Translational Relevance 
Although considered a chemo-responsive disease, a proportion of high grade serous ovarian 
cancer (HGSOC) patients do not respond to platinum-based chemotherapy at initial 
presentation. Clinically validated biomarkers of lack of response would enable alternative 
treatment stratification for these patients and identify novel mechanisms of resistance. We 
have identified CpG sites at contiguous genomic locations within the homeobox MSX1 gene 
as significantly associated with lack of response of HGSOC patients in discovery, test and 
validation patient cohorts. A decrease in methylation was significantly correlated with 
decreased MSX1 gene expression. Increased expression of MSX1 in three TP53 mutant or 
wild-type expressing, platinum-resistant ovarian cancer lines led to cisplatin sensitisation and 
increased p21 expression. However, in two TP53-null cell lines, MSX1 failed to change 
cisplatin sensitivity. In conclusion, hypomethylation and expression of MSX1 is a biomarker 
of resistant HGSOC disease at presentation and identifies a novel mechanism of platinum 
drug resistance. 
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Abstract  
Purpose: Although High Grade Serous Ovarian Cancer (HGSOC) is frequently chemo-
responsive, a proportion of patients do not respond to platinum-based chemotherapy at 
presentation or have progression-free survival of less than 6 months. Validated predictive 
biomarkers of lack of response would enable alternative treatment stratification for these 
patients and identify novel mechanisms of intrinsic resistance.  
 
Experimental Design: DNA methylation was investigated in independent tumour cohorts 
using Illumina HumanMethylation arrays and validated by bisulphite pyrosequencing. Gene 
expression was examined by Affymetrix arrays and qRT-PCR. The role of Msh homeobox 1 
(MSX1) in drug sensitivity was investigated by gene reintroduction into ovarian cancer cell 
lines.  
 
Results: CpG sites at contiguous genomic locations within the MSX1 gene have significantly 
lower levels of methylation in independent cohorts of HGSOC patients which recur by 6 
months compared to after 12 months and/or with poor RECIST response (p<0.05, q<0.05). A 
decrease in methylation at these CpG sites correlates with decreased MSX1 gene 
expression. Low expression of MSX1 is associated with poor progression-free survival 
independent of known clinical prognostic features (p=0.014). Three mutant or wild-type TP53 
expressing ovarian cancer cell lines, resistant to cisplatin, have reduced MSX1 expression 
compared to matched parental, platinum sensitive, lines. Re-expression of MSX1 in resistant 
lines led to cisplatin sensitisation and increased cisplatin induced p21 expression. However, 
in two TP53-null cell lines, MSX1 failed to change cisplatin sensitivity or p21 expression.  
 
Conclusions: Hypomethylation of MSX1 is associated with resistant HGSOC disease at 
presentation and identifies a novel mechanism of platinum drug resistance. 
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Introduction 
Epithelial ovarian cancer (EOC) is the second commonest, but most lethal, of the 
gynaecological malignancies, with overall 5 year survival rates around 45% [Reviewed in (1, 
2)]. Adjuvant chemotherapy is recommended for those with stage 1C disease or higher and 
normally comprises of platinum based agent with or without taxol (3). Despite this, 
approximately 20% of patients will be resistant to first line platinum agents and prognosis in 
these platinum resistant patients is particularly poor (2). Currently there are no reliable 
methods to determine or predict platinum resistance and thus patients who will gain little 
clinical benefit undergo treatment regimes associated with high morbidity and side effects. 
Defective Homologous Recombination shows promise as a marker of platinum response, 
although has limited sensitivity and specificity (4) and ultimately combinations of 
independent predictive biomarkers of response are likely to be required. Biomarkers which 
predict treatment response may identify novel targets for therapies aimed at reversal of 
resistance and will facilitate stratification of patients who should be considered for alternative 
treatment with non-cytotoxic, molecularly targeted agents.   
The use of DNA methylation as a biomarker has several advantages over other molecular 
endpoints, including sensitivity and stability of DNA methylation, as well as less confounding 
effects of contaminating normal tissue in patient-derived biopsies. Furthermore, DNA 
methylation measurements can be compared to absolute reference points (for instance, 
completely methylated or completely unmethylated DNA), which provides a quantitative 
assays (5). Additionally, tumour DNA methylation can be detected in body fluids of patients, 
potentially leading to measurement of tumour-derived biomarkers non-invasively (5). There 
are now numerous examples of the potential of DNA methylation as a therapy stratification 
biomarker or as marker of acquired resistance, although few methylation biomarkers have 
been clinically validated or used as stratification biomarkers in clinical studies (6).   
We have examined DNA methylation in high grade serous ovarian cancer using Illumina 27K 
HumanMethylation array data in independent tumour cohorts for cross-validation. This 
analysis identified methylation at the Homeobox gene MSX1 as associated with platinum 
resistant disease. Dysregulation of HOX genes have been associate with a variety of human 
cancers [summarised in (7)]. Msh homeobox 1 (MSX1), also known as HOX7, is a 
homeobox gene with critical roles in the control of cellular differentiation in development (8) 
(9). MSX1 has been shown to cause a change in cell morphology and a reduction in cell 
growth by induction of apoptosis in HeLa cancer cells (10). We have examined the role of 
MSX1 in chemosensitivity by gene reintroduction into platinum resistant ovarian tumour cell 
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lines that have reduced MSX1 expression compared to matched parental, non-platinum 
exposed, lines.  
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Methods 
Patient samples 
Fresh-frozen EOC tissue was collected and stored at -80 ᵒC at Imperial College NHS Trust 
Tissue Bank, Hammersmith Hospital (“Hammersmith Cohort”). Tumours selected were from 
primary debulking surgery (no previous chemotherapy), advanced stage disease (FIGO 
stage 3 and 4) with high grade (G2-3) serous histology. Patients were excluded with mixed 
cell or borderline pathology. In order to assess the quality of the individual fresh frozen tissue 
samples used for DNA extraction, adjacent tissue was histopathologically examined and 
samples excluded with low tumour cell content.  
Overall survival (OS) and progression free survival (PFS) were defined as the interval from 
the date of initial surgical resection to the date of last known contact, or death for overall 
survival and the interval from the date of initial surgical resection to the date of progression 
or recurrence for progression free survival. Stage was defined using FIGO criteria.  
Response to chemotherapy was defined by RECIST 1.1 (11) criteria using scans done at 
two distinct time points, CT chest, abdomen and pelvis scan post-surgery but prior to 
adjuvant chemotherapy, and after 6 cycles of chemotherapy. Patients were categorised into 
two groups, those who responded to chemotherapy (complete or partial response) or with 
stable disease were compared to those with progressive disease only.  
The clinical characteristics of the Hammersmith Cohort and the The Cancer Genome Atlas 
samples used for validation (“TCGA Cohort”) are shown in Supplementary Table S1. 
Bisulphite conversion 
Up to 500mg of tumour tissue was used per sample and DNA extracted by the chlorinated 
Nucleon extraction method (Gen-Probe Life Sciences Ltd.) and resuspended in TE buffer 
(10mM Tris, 1mM EDTA, pH8). Tumour DNA was bisulphite converted using the EZ-96 DNA 
Methylation™ Kit (Zymo) as per manufacturers protocol. 1μg of genomic DNA was used for 
each sample. Successful bisulphite conversion was confirmed by successful conversion of 
cytosines at calponin locus (12).   
Infinium HumanMethylation27 beadchip 
Samples were processed as per the Infinium Assay Methylation Protocol Guide (Illumina) 
(http://www.illumina.com/products/infinium_humanmethylation27_beadchip_kits.ilmn#docum
entation). Following bisulphite conversion, 200 ng per samples were resuspended at 
50ng/μl. Methylation data was summarized as β values, calculated as M/(M+U) where M is 
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signal from methylated beads and U is signal from unmethylated beads at the targeted CpG 
site. β values were adjusted for background and data was log transformed to achieve a 
normal distribution for both TCGA and the beadchip. Probes with a detection p value of 
>0.05 were removed. Quality control checks were performed through Genome Studio.  
TCGA dataset analysis 
Illumina Human Methylation27 Beadchip data on HGSOC from The Cancer Genome Atlas 
data portal (http://cancergenome.nih.gov/dataportal) (“TCGA Cohort”) was used for 
independent validation of correlations observed in the Hammersmith cohort. Level 2 
expression data on Affymetrix HGU133A microarrays, level 3 methylation data and 
annotated clinical data were obtained. The expression microarray data was pre-processed 
and normalised across samples.  
Plasmid transfection 
Cell lines used are described in Supplementary Table 2. Cells were stable transfected either 
with MSX1 expression plasmid obtain from Origene (RC205682) or the corresponding empty 
vector (PS100001) using FUGENE HD transfection reagent (Promega) as per respective 
protocols. Cells were grown and maintained under 500µg/ml of Geneticin® (Life 
techologies). 
Real Time-PCR and gene expression profiling 
To analyse gene expression, two-step reverse transcription PCR was performed. Total RNA 
was extracted using the QIAshredder and RNAeasy Mini Kits (Qiagen) according to 
manufacturers protocol.  Total RNA  was converted to cDNA using High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems). qPCR was performed using Fast SYBR® 
Green Master Mix (Applied Biosystems)  using specific primers. Each reaction was 
performed following the manufactory recommendations using 10 ng of converted RNA. The 
data was analysed using the ∆∆Ct method. For MSX1 gene expression, qRT-PCR was 
performed using Taqman primers (MSX1 Hs 00427183_m1 (Applied Biosystems)) compared 
to endogenous control (beta-actin) and StepOnePlus Real-Time PCR Systems (Applied 
Biosystems).  
Cell proliferation assays  
Cells were seeded at 10,000 cells per well in triplicate, after 24 hours cells were treated with 
Cisplatin at concentrations of 0 µM to 50 µM for 24 hours. Cell proliferation was quantified 
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with MTT assay after a further 48 hours of culture after 24 hours of cisplatin treatment using 
CellTitre 96 Aqueous One Solution Proliferation Assay (Promega).  
Statistics 
All statistical analyses were performed using the R statistical package (version 2.10 at 
http://www.r-project.org). Individual generalized linear regression models were performed 
adjusting for array batch, grade and residual disease in order to determine significant 
differentially methylated loci and associated differential gene expression of Affymetrix gene 
expression data with RECIST chemotherapy response, and PFS <6months versus 
>12months in both datasets. A significant relationship between TCGA DNA methylation and 
gene expression in the tumour tissue was determined through Spearman correlation.   
For gene expression using FastSYBR Green, the standard error of mean (SEM) was 
calculated for three independent experiments. To determine the statistical significance of the 
differences observed, an unpaired student t-test was used. The differences were considered 
significant when a two-sided P-value was below 0.05. (* - P<0.05, ** - P<0.01, *** - P<0.005) 
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Results 
Hypomethylation of MSX1 in HGSOC is associated with progressive disease and short 
progression free survival  
Discovery analysis across all loci on the 27K Illumina bead array, comparing HGSOC 
patients from a Hammersmith Cohort (n=78) with progressive disease (PD) versus those 
who responded to chemotherapy or had stable disease, identified multiple CpG sites at the 
MSX1 gene which demonstrated significant differential methylation, even after taking 
multiple comparisons into account (p<0.05, FDR <5%). We further evaluated this 
relationship in a cohort (n=61) of Hammersmith patients with response data defined by 
RECIST 1.1 criteria (Table 1). We observe 8 contiguous CpG sites spanning the first intron 
and 2nd exon of MSX1 to be significantly (p<0.05) associated with RECIST response (Figure 
1).  For 7 out of 8 significant probes methylation was significantly lower in the group with 
progressive disease versus those with response to chemotherapy or stable disease, with a 
methylation difference of >15% (Supplementary figure S1). Progression-free survival (PFS) 
of less than 6 months is widely used to clinically define platinum resistant disease, while PFS 
greater than 12 months is often used to define platinum sensitive disease (13). Six of the 8 
CpG sites within the MSX1 gene identified as associated with response have significantly 
lower levels of methylation in HGSOC from the Hammersmith cohort which recur by 6 
months compared to after 12 months (p<0.05, q<0.05), with the remaining two showing a 
similar trend (Table 1). 
Primary chemotherapy response was not defined by RECIST criteria in the TCGA dataset, 
and therefore could not be used to validate the association with response observed in the 
Hammersmith cohort. However, PFS data was available in the TCGA dataset for 146 
patients and methylation data available for 7 of the 8 MSX1 probes identified from the 
Hammersmith Cohort (Table 1 and Figure 1). Linear regression models adjusting for array 
batch, grade and residual disease found methylation levels at 4 probes to be significantly 
associated with PFS and a further 2 showing strong trend. Consistent with the Hammersmith 
dataset, methylation at these CpGs demonstrated a corresponding lower level of methylation 
in patients with PFS <6 months. 
 
MSX1 gene expression is associated with DNA methylation and progression-free survival 
DNA methylation and gene expression data was available for 252 samples in the TCGA 
data. This data demonstrated that a decrease in methylation at 6 of the identified CpG sites 
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were significantly correlated (p<0.05) to a decrease in gene expression (Table 1 and Figure 
1). MSX1 expression and progression free survival (PFS) were significantly associated in the 
TCGA cohort dataset using univariate Cox proportional hazard regression analysis (Hazard 
Ratio, 0.92, 95% CI 0.85-0.99, p=0.029, n=309).  Patients with low expression of MSX1 had 
poorer PFS than those with higher MSX1 expression. A significant association was retained 
in multivariable Cox analysis when age, grade, stage and residual disease were included in 
the model (p=0.014), demonstrating that MSX1 expression is an independent biomarker 
from clinical factors known to be associated with PFS. 
  
MSX1 sensitises cells expressing TP53, but not null-TP53 cells 
Relative MSX1 gene expression was examined by qRT-PCR on three matched pairs of 
cisplatin sensitive and resistant ovarian cancer cell lines: PEA1/PEA2, PEO1/PEO4 and 
PEO14/PEO23 pairs derived from HGSOC patients before treatment and at relapse after 
platinum-based chemotherapy (14) and A2780/A2780cp70 sensitive and in vitro derived 
resistant line (15). Gene expression was markedly lower in the platinum resistant cell lines 
derived from patients following chemotherapy or in vitro derived compared to their platinum 
sensitive pair (Figure 2). However, no significant difference in DNA methylation could be 
detected between the pairs of cell lines (data not shown). In order to examine whether 
increased MSX1 expression would increase the cells sensitivity to cisplatin, the ovarian cell 
lines A2780cp70, PEA2, and PEO4 were stably transfected either with an MSX1 containing 
plasmid (MSX1) or with the corresponding empty vector (EV). As shown in Figure 3, all three 
ovarian cancer cell lines transfected with MSX1 showed an increase in cisplatin sensitivity 
compared to the empty vector control. The HGSOC cell lines PEA2 and PEO4 stable 
overexpressing either MSX1 or the corresponding EV were treated with cisplatin and the 
expression of p21 and MSX1 was analysed by qRT-PCR. Overexpression MSX1 increases 
the expression of p21 after cisplatin treatment, when compared to the EV transfectants 
(Figure 3).  
MSX1 has previously been shown to interact with p53 and increased p53-dependent 
apoptosis (10). In HGSOC, p53 is mutated in about 97% of cases, although often will still 
express mutant forms of p53 (16). The TP53 mutations described in the literature for the cell 
lines used were confirmed and the ovarian cell lines examined all express either wildtype or 
mutant alleles of TP53 (Supplementary Table S2). MSX1 was also transfected into the 
ovarian adenocarcinoma SKOV3 (Supplementary Table S2). In SKOV3, no TP53 mRNA is 
detected and, consequently, the protein is absent (17). In SKOV3, MSX1 overexpression did 
not change the cisplatin sensitivity nor the expression of p21 after 24 hours of cisplatin 
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treatment (Figure 4). To further examine effects of MSX1 in a null p53 cell line, the p53-null 
lung cancer cell line H1299 was transfected with MSX1. Again in H1299, MSX1 
overexpression did not change the cisplatin sensitivity nor the expression of p21 after 24 
hours of cisplatin treatment (Figure 4).   
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Discussion 
In independent tumour cohorts, differential methylation of multiple CpG sites at an intragenic 
region of the homeobox gene MSX1 spanning the intron and second exon is significantly 
associated with primary chemotherapy resistance and poor progression free survival in 
HGSOC. Increased methylation significantly correlates with increased gene expression. 
MSX1 encodes a member of the muscle segment homeobox gene family and its expression 
is associated with epithelia-mesenchymal interactions during embryogenesis (18). 
Intriguingly, the same 8 CpG sites we observe associated with response to chemotherapy in 
MSX1 have been associated with fetal heart malformation and again increased methylation 
is associated with an increase in MSX1 expression (19). Given the suggestion by the authors 
that DNA methylation at these CpG sites impairs MSX1-dependent mesenchymal 
embryogenesis it is tempting to speculate that MSX1 in ovarian cancer may influence 
epithelial-mesenchymal transition (EMT) which has been implicated in resistance of ovarian 
tumours to chemotherapy (20). 
Binding of MSX1 in the genome of myoblasts promotes enrichment of the repressive 
H3K9me2 mark via recruitment of EHMT2 (G9a) histone methyltransferase (21), the enzyme 
responsible for maintaining this histone mark. Given the involvement of epigenetic regulation 
in drug resistance (6), it is therefore possible that MSX1 is mediating its effects on 
chemosensitivity through epigenetic regulation. An alternative explanation of MSX1 effects 
on chemosensitivity could be through p53 stabilisation. Previous studies have suggested 
that MSX1 decreased cell growth and induced apoptosis in HeLa cell lines through 
stabilisation of p53, decreased degradation and increasing nuclear localisation (10). We 
observe chemosensitisation of MSX1 in cell lines, which still express mutant or wild-type 
TP53, but not in TP53 null cell lines. Interestingly, EHMT2 methylates lysine 373 in p53 (22). 
Potential hypotheses to be examined in future studies would be whether MSX1 cooperates 
with G9a/EHMT2 in methylating p53 (and related p63 and p73 proteins) leading to changes 
in cisplatin sensitivity or whether MSX1/EHMT2 mediated changes in histone H3K9 
methylation can directly influence expression of genes associated with drug resistance. 
Both tumour cohorts use fresh frozen tumour that is not microdissected and heterogenous 
cell types within each sample may confound overall gene expression data, although will be 
expected to have less impact on DNA methylation data. There was no correlation between 
methylation data in the Hammersmith cohort and the percentage of tumour nuclei, therefore 
there is no bias in the proportions of tumour and normal cells in biopsies influencing the 
association observed (data not shown).  
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A limitation of the TCGA data is that the primary chemotherapy response was not defined by 
RECIST criteria and so could not be used to validate the association with response observed 
in the Hammersmith cohort. Instead we have used PFS to validate the associations 
observed. PFS of less than 6 months is widely used to clinically define platinum resistant 
disease, while PFS greater than 12 months is often used to define platinum sensitive 
disease (13, 23). Analysis of the TCGA data validated the association with PFS observed in 
the Hammersmith cohort at 4 CpG MSX1 sites, with others showing similar trend. Consistent 
with the Hammersmith cohort, CpG sites demonstrated a corresponding lower level of 
methylation in patients with PFS <6 months. It should be noted that the TCGA data 
represents analysis of tumours collected across multiple clinical sites and the robustness 
and reliability of clinical data from multiple centres may not be as well controlled as in the 
single site Hammersmith data. Indeed analysis of the TCGA data does not show some of the 
expected clinical correlations, such as association between survival and surgical debulking 
(data not shown). 
We have identified methylation and expression of MSX1 as a biomarker of lack of response 
to primary chemotherapy in HGSOC. Clinical stratification based on such biomarkers could 
enable alternative treatment stratification for these patients at presentation or of 
maintenance therapies during remission. The functional role of MSX1 and its role potentially 
in epigenetic regulation or methylation of cellular proteins such as p53 needs further in-depth 
study.  
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Figure Legends 
Figure 1: Schematic of MSX1 locus showing CpG sites associated with clinical outcome. 
 
Figure 2. MSX1 gene expression in cisplatin sensitive (Black bar) and resistant (white 
bar) cell line pairs. RNA levels of MSX1 gene were analysed by qRT-PCR and normalised 
against β-actin. Statistical analysis was performed using standard error of the mean (SEM) 
and Student t-test (* - P<0.05, ** - P<0.01 and *** - P<0.005). 
 
Figure 3. MSX1 overexpression re-sensitises cells to cisplatin treatment. MSX1 
expression vector and empty vector (EV) transfected cell lines PEA2 (A.) PEO4 (B.) CP70 
(C.) were treated with cisplatin for 24h. MTT assay was performed 48h after treatment. Data 
is representative of at least three independent experiments. D. PEA2 and PEO4 cell were 
treated with the indicated cisplatin concentrations for 24 hours. p21 RNA levels were 
analysed relative to. β-actin by qRT-PCR. Statistical analysis was performed using standard 
error of the mean (SEM) and Student t-test (* - P<0.05, ** - P<0.01 and *** - P<0.005). 
 
Figure 4. MSX1 overexpression does not sensitise cells to cisplatin in p53-null cells. 
MSX1 expression vector and empty vector (EV) transfected cell lines SKOV3 (A.) and 
H1299 (B.) were incubated with the indicated cisplatin concentration for 24 after which either 
MTT assay was performed as described before. C. p21 expression was measured by 
qRTPCR in SKOV3 and H1299 cells. Statistical analysis was performed using standard error 
of the mean (SEM) and Student t-test (* - P<0.05, ** - P<0.01 and *** - P<0.005). 
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Figure 2. MSX1 gene expression in cisplatin sensitive (Black bar) and 
resistant (white bar) cell line pairs. 
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Figure 3. MSX1 overexpression re-sensitises cells to cisplatin treatment. 
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Figure 4. MSX1 overexpression does not sensitise cells to cisplatin in 
p53-null cells. 
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Probe ID p value q value Chemotherapy response
Progressive 
disease
Δ 
Methylation p value q value
PFS>12 
mths
PFS<6 
mths
Δ 
Methylation p value q value
PFS>12 
mths PFS<6 mths p value rho
cg22609784 <0.001 0.002 0.65 0.27 0.39 0.009 0.032 0.65 0.53 0.12 0.023 0.114 0.77 0.68 0.058 0.119
cg09573795 0.018 0.045 0.76 0.78 -0.02 0.082 0.159 0.76 0.67 0.08 0.039 0.115 0.83 0.79 0.013 0.157
cg27038439 <0.001 0.002 0.91 0.73 0.18 0.011 0.034 0.91 0.75 0.16 NA NA NA NA NA NA
cg24840099 <0.001 <0.001 0.78 0.34 0.45 0.000 0.001 0.78 0.34 0.45 0.053 0.115 0.85 0.82 0.003 0.184
cg09748975 <0.001 <0.001 0.88 0.55 0.33 0.000 0.001 0.88 0.56 0.32 0.042 0.115 0.96 0.95 0.019 0.147
cg03843978 0.028 0.055 0.61 0.46 0.15 0.089 0.159 0.61 0.48 0.13 0.188 0.283 0.67 0.67 0.019 0.148
cg20891301 0.021 0.046 0.75 0.57 0.18 0.002 0.010 0.75 0.57 0.17 0.05 0.115 0.90 0.87 0.031 0.136
cg01785568 0.005 0.015 0.69 0.43 0.26 0.002 0.010 0.71 0.45 0.27 0.067 0.126 0.80 0.63 <0.001 0.497
NA Data not available
HH: Hammersmith Cohort
TCGA: The Cancer Genome Atlas Cohort
Median methylation (beta 
value) 
PFS <6 months, versus >12 months, n=146, TCGA
DNA methylation to 
gene expression 
correlation
TCGA, n=252
Linear regression 
model Median methylation (beta value) 
RECIST chemotherapy response, n=61 HH
Linear regression 
model
PFS <6 months, versus >12 months, n=39 HH
Linear regression modelMedian methylation (beta value) 
